Enterprise Value

278.4B

Cash

9.767B

Avg Qtr Burn

N/A

Short % of Float

0.00%

Insider Ownership

0.00%

Institutional Own.

0.66%

Qtr Updated

12/31/22


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
Polivy (CD79b) w/ R-CHP Details
Cancer, Diffuse large B cell lymphoma

Approved

Quarterly sales

Mosunetuzumab (Lunsumio) Details
Blood cancer, Cancer, Follicular lymphoma

Approved

Quarterly sales

PDUFA

Approval decision

PDUFA

Approval decision

Crovalimab Details
Paroxysmal nocturnal hemoglobinuria

Phase 3

Data readout

Fenebrutinib Details
Multiple sclerosis, Autoimmune disease

Phase 3

Data readout

Tecentriq® (atezolizumab) +Avastin® Details
Solid tumor/s, Cancer, Hepatocellular carcinoma

Phase 3

Update

Gantenerumab Details
Alzheimer's disease

Phase 3

Update

Anti-IL-6 monoclonal antibody Details
Eye disease , Macular edema

Phase 1

Update